A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers.
This year, 2008, marks the 10-year anniversary of the development of the modern tissue microarray (TMA). During the last decade, the use of TMAs has grown steadily and accounts for a small but increasing percentage of all cancer biomarker studies performed. The growing popularity of TMA-based studies attests to their benefits in the discovery and validation of new biomarkers. This review will focus on these benefits, but also on the faults of TMAs and the challenges of TMA studies that have been overcome in the last decade. We will also discuss the role of TMAs in the latest revolution in cancer treatment, the use of targeted drug therapy.
Camp
Robert L
RL
Department of Pathology, Yale University School of Medicine, 310 Cedar St, PO Box 208023, New Haven, CT 06520-8023, USA.
Neumeister
Veronique
V
Rimm
David L
DL
D001331:Automation; D014408:Biomarkers, Tumor / Q000378:metabolism*; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D008495:Medical Oncology / Q000379:methods; D009369:Neoplasms / Q000175:diagnosis* / Q000378:metabolism; D015203:Reproducibility of Results; D046888:Tissue Array Analysis / Q000295:instrumentation* / Q000379:methods*
D014408:Biomarkers, Tumor